[{"id":"301f8b06-1a2c-40a7-8a67-b9e2243e1a5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02885766","created_at":"2021-01-18T14:09:52.259Z","updated_at":"2024-07-02T16:36:49.972Z","phase":"Phase 1/2","brief_title":"Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene","source_id_and_acronym":"NCT02885766","lead_sponsor":"Fusion Pharma LLC","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vamotinib (PF-114)"],"overall_status":"Unknown status","enrollment":" Enrollment 65","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-02-17"}]